Related Experiment Video
Updated: May 7, 2026
12:33
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
65.5K
Allicin and its Therapeutic Potential in Diabetes Management: A Comprehensive Review
Anmol Saini1, Vishakha Saini1, Suresh Kumar2
1Global Research Institute of Pharmacy, Yamuna Nagar, Haryana, 135133, India.
Current Aging Science
|July 2, 2025
Summary
Allicin, a compound found in garlic, shows promise in managing diabetes mellitus (DM). Studies indicate allicin may help regulate blood sugar and protect against diabetic complications, making it a potential therapeutic agent.
Area of Science:
- Biochemistry
- Pharmacology
- Endocrinology
Background:
- Diabetes mellitus (DM) is characterized by hyperglycemia due to impaired insulin secretion or action.
- Pancreatic beta-cell destruction and insulin resistance are key pathogenic mechanisms in DM.
- Garlic (Allium sativum) contains various beneficial compounds, including allicin.
Purpose of the Study:
- To review the potential benefits of allicin in managing diabetes mellitus (DM).
- To explore the therapeutic applications of allicin in relation to diabetic complications.
Main Methods:
- Comprehensive literature search of databases (PubMed, Web of Science, Scopus).
- Review of clinical trial data from ClinicalTrials.gov.
- Analysis of in vitro studies on allicin's effects on cell lines.
Main Results:
- Allicin demonstrated potential benefits for pancreatic cells, wound healing, and insulin secretion.
- Studies showed allicin's inhibitory effects on diabetes mellitus in cell line experiments.
- Allicin may help maintain glucose homeostasis and address diabetic complications like nephropathy and macroangiopathy.
Conclusions:
- Allicin exhibits promising therapeutic benefits and inhibitory actions against diabetes mellitus.
- Further research into allicin's application for diabetes treatment is warranted.
- Allicin is a potential candidate for novel diabetes mellitus therapies.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:22Diabetic Neuropathy
59
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
59